Ewing sarcoma

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…

This phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has come back or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. Researchers are checking whether the canc…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This study tests whether adding a targeted drug called ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. The trial includes 312 participants and aims to see if the combination improves survival without the cancer growing back. The…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This phase II trial is testing whether adding two chemotherapy drugs, irinotecan and temozolomide, to the standard treatment for newly diagnosed Ewing sarcoma can improve outcomes. The study includes 83 patients aged 1 to 40. Researchers hope the extra drugs will help prevent the…

This study is testing a new way to choose chemotherapy for children with high-risk or relapsed soft tissue sarcomas. Doctors grow a miniature version of the patient's tumor in the lab (called an organoid) and test different drugs on it to see which works best. The goal is to see …

This study tests whether adding the drug abemaciclib to standard chemotherapy can help people with Ewing's sarcoma whose cancer has returned or not responded to treatment. About 46 children and young adults will take part. The goal is to see if the combination slows tumor growth …

This early-stage trial tests a treatment made from a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL). Doctors remove a piece of the tumor, grow the immune cells in a lab, and then infuse them back into the patient to attack the cancer. The study includes 4…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This study tests a precise radiation technique called image-guided radiotherapy (IGRT) for children and young adults with bone or soft tissue tumors. By using CT, MRI, and PET scans to pinpoint the tumor, doctors aim to deliver radiation more accurately and reduce damage to healt…

This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…

This study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have returned or not responded to treatment. The drug works by blocking an enzyme that cancer cells need to grow. The trial aims to find the safest dose and see if the drug c…

This early-phase study tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The trial enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The goal is to find a s…

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This study is testing whether a liquid biopsy (a blood test that detects tumor DNA) can help predict outcomes for people with Ewing sarcoma or osteosarcoma. Researchers will collect blood samples from 340 patients at diagnosis and track their health over time. The goal is to see …

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time p…

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…